Kenvue, the Johnson & Johnson spinoff that is the world’s largest pure-play consumer health company by revenue, announced Thursday that its near-term greenhouse gas emissions reduction targets have been validated by the Science Based Targets initiative.
SBTi, a leading corporate climate action organization, looked at Kenvue’s emission targets and validated that they are in line with their end goals — and in line with the urgent actions needed to limit the global temperature rise to 1.5°C.
Kenvue has:
- Committed to reducing its absolute Scope 1 and 2 GHG emissions 42% by 2030 from a 2020 base year;
- Committed that 75% of its suppliers by emissions covering purchased goods and services and upstream transportation and distribution will have science-based targets by 2028.
Pamela Gill-Alabaster, the global head of environmental, social & governance and sustainability at Kenvue, said the acknowledgement is significant.
“We are proud that the SBTi has validated our climate targets so early in our new company’s journey, and this important milestone signals our intent to create a positive change and make meaningful progress in support of our Healthy Lives Mission,” she said.
“We recognize the increasingly detrimental impact climate change is having on people and ecosystems around the world. As a company dedicated to a healthy future, we are setting ambitious science-based emissions reduction targets and action plans to decarbonize our products, operations and value chain.”
Company officials said these validated near-term targets, and the Kenvue commitment to set long-term net zero emissions targets informed by the SBTi Net Zero Standard, support Kenvue’s Healthy Lives Mission, the company’s ESG strategy.
With the understanding that human health is inseparably linked to environmental health, Kenvue’s Healthy Lives Mission aims to advance the well-being of both people and planet and sets goals and commitments to help drive impact, company officials said.
